HRP20241255T1 - Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina - Google Patents
Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina Download PDFInfo
- Publication number
- HRP20241255T1 HRP20241255T1 HRP20241255TT HRP20241255T HRP20241255T1 HR P20241255 T1 HRP20241255 T1 HR P20241255T1 HR P20241255T T HRP20241255T T HR P20241255TT HR P20241255 T HRP20241255 T HR P20241255T HR P20241255 T1 HRP20241255 T1 HR P20241255T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- independently
- image
- occurrence
- nrac
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims 10
- 108020004707 nucleic acids Proteins 0.000 title claims 4
- 102000039446 nucleic acids Human genes 0.000 title claims 4
- 150000007523 nucleic acids Chemical class 0.000 title claims 4
- 239000002105 nanoparticle Substances 0.000 title claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 46
- 229910052799 carbon Inorganic materials 0.000 claims 29
- 150000001721 carbon Chemical group 0.000 claims 28
- -1 cationic lipid Chemical class 0.000 claims 17
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 230000007935 neutral effect Effects 0.000 claims 5
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 claims 2
- NONFBHXKNNVFMO-UHFFFAOYSA-N [2-aminoethoxy(tetradecanoyloxy)phosphoryl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OP(=O)(OCCN)OC(=O)CCCCCCCCCCCCC NONFBHXKNNVFMO-UHFFFAOYSA-N 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyethers (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886894P | 2019-08-14 | 2019-08-14 | |
| EP20765121.7A EP4013385B1 (en) | 2019-08-14 | 2020-08-14 | Improved lipid nanoparticles for delivery of nucleic acids |
| PCT/US2020/046407 WO2021030701A1 (en) | 2019-08-14 | 2020-08-14 | Improved lipid nanoparticles for delivery of nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241255T1 true HRP20241255T1 (hr) | 2024-12-06 |
Family
ID=72322523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241255TT HRP20241255T1 (hr) | 2019-08-14 | 2020-08-14 | Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20230097090A1 (https=) |
| EP (2) | EP4454640A3 (https=) |
| JP (2) | JP7753190B2 (https=) |
| KR (1) | KR20220053599A (https=) |
| CN (1) | CN114901253A (https=) |
| AU (1) | AU2020328596B2 (https=) |
| BR (1) | BR112022002708A2 (https=) |
| CA (1) | CA3150458A1 (https=) |
| CL (1) | CL2022000351A1 (https=) |
| CO (1) | CO2022002685A2 (https=) |
| CR (1) | CR20220108A (https=) |
| DE (1) | DE112020003843T5 (https=) |
| DK (1) | DK4013385T3 (https=) |
| DO (1) | DOP2022000038A (https=) |
| EC (1) | ECSP22018209A (https=) |
| ES (2) | ES2992930T3 (https=) |
| FI (1) | FI4013385T3 (https=) |
| GB (1) | GB2600859B (https=) |
| GE (2) | GEAP202515904A (https=) |
| HR (1) | HRP20241255T1 (https=) |
| HU (1) | HUE068356T2 (https=) |
| IL (1) | IL290477A (https=) |
| JO (1) | JOP20220037A1 (https=) |
| LT (1) | LT4013385T (https=) |
| MX (2) | MX2022001720A (https=) |
| PE (1) | PE20220968A1 (https=) |
| PH (1) | PH12022550363A1 (https=) |
| PL (1) | PL4013385T3 (https=) |
| PT (1) | PT4013385T (https=) |
| SI (1) | SI4013385T1 (https=) |
| UA (1) | UA129330C2 (https=) |
| WO (1) | WO2021030701A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| JP7543259B2 (ja) | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| WO2020097493A1 (en) | 2018-11-09 | 2020-05-14 | Arbutus Biopharma Corporation | Negatively charged peg-lipid conjugates |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| CN113402404B (zh) * | 2021-04-30 | 2022-03-11 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| KR20240008872A (ko) * | 2021-05-06 | 2024-01-19 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온화 가능한 양이온성 지질 |
| CN115385820B (zh) * | 2021-05-09 | 2025-04-29 | 英维沃生物科技(苏州)有限公司 | 阳离子脂质及其应用 |
| US12508225B2 (en) | 2021-05-28 | 2025-12-30 | Beijing Tricisionbio Therapeutics Inc. | Lipid compound and use thereof in delivery of nucleic acid |
| CN113403313B (zh) * | 2021-06-23 | 2022-08-19 | 北京理工大学 | 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用 |
| EP4342929B1 (en) * | 2021-06-30 | 2026-02-04 | Jenkem Technology Co. Ltd. (Tianjin) | Polyethylene glycol lipid and use thereof |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN115403761B (zh) * | 2021-07-23 | 2025-04-25 | 天津键凯科技有限公司 | 一种多元甘醇修饰的脂质化合物及其制备方法和应用 |
| CN115710191B (zh) * | 2021-08-23 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| CN115869262A (zh) * | 2021-09-27 | 2023-03-31 | 广州谷森制药有限公司 | 新型peg脂质化合物、其制备方法、组合物及应用 |
| AR127312A1 (es) * | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
| WO2023061460A1 (zh) * | 2021-10-15 | 2023-04-20 | 厦门赛诺邦格生物科技股份有限公司 | 含氮的阳离子脂质及其应用 |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| JP2024544953A (ja) * | 2021-11-11 | 2024-12-05 | オハイオ ステート イノベーション ファウンデーション | アミノ脂質化合物を含む組成物ならびにその製造方法及び使用方法 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CN114957027B (zh) * | 2022-01-13 | 2023-05-19 | 北京悦康科创医药科技股份有限公司 | 一种阳离子脂质化合物、包含其的组合物及用途 |
| TW202330457A (zh) * | 2022-01-19 | 2023-08-01 | 大陸商蘇州艾博生物科技有限公司 | 脂質化合物和脂質奈米顆粒組合物 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116969851A (zh) * | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| CN117263818A (zh) * | 2022-06-14 | 2023-12-22 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
| CN114989182B (zh) * | 2022-06-23 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 脂质化合物、包含其的组合物及应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN117417264B (zh) * | 2022-07-19 | 2025-12-16 | 深圳深信生物科技有限公司 | 氨基脂质化合物、其制备方法和应用 |
| WO2024022263A1 (zh) * | 2022-07-25 | 2024-02-01 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| EP4565572A1 (en) * | 2022-08-05 | 2025-06-11 | Life Technologies Corporation | Lipids for nucleic acid delivery |
| JP2025530171A (ja) * | 2022-09-07 | 2025-09-11 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤で使用するための脂質 |
| CN120554239A (zh) * | 2022-09-09 | 2025-08-29 | 厦门赛诺邦格生物科技股份有限公司 | 一种碳核阳离子脂质 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| CN115417779B (zh) * | 2022-11-03 | 2023-06-16 | 北京华芢生物技术有限公司 | 可离子化的阳离子脂c6-a1及由其组成的纳米脂质体颗粒 |
| CN115417780B (zh) * | 2022-11-04 | 2023-06-20 | 北京华芢生物技术有限公司 | 可离子化的阳离子脂c5-a2及由其组成的纳米脂质体颗粒 |
| WO2024119098A1 (en) * | 2022-12-02 | 2024-06-06 | Prime Medicine, Inc. | Lipid nanoparticle (lnp) delivery systems and formulations |
| WO2024131810A1 (en) * | 2022-12-21 | 2024-06-27 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticles comprising sterol-modified phospholipids |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| CN118666726A (zh) * | 2023-03-17 | 2024-09-20 | 尧唐(上海)生物科技有限公司 | 递送治疗剂的脂质化合物及其制备方法与应用 |
| EP4704855A1 (en) * | 2023-04-26 | 2026-03-11 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| CN117384055B (zh) * | 2023-04-27 | 2024-11-19 | 仁景(苏州)生物科技有限公司 | 用于递送治疗剂的可电离脂质及其用途 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| CN116891423B (zh) * | 2023-07-07 | 2024-03-01 | 荣灿生物医药技术(上海)有限公司 | 脂质化合物、组合物及其制备方法和应用 |
| CN119791061A (zh) * | 2023-10-11 | 2025-04-11 | 中国人民解放军军事科学院军事医学研究院 | 一种甲型肝炎病毒感染动物模型的构建方法及其用途 |
| US20250161227A1 (en) | 2023-11-17 | 2025-05-22 | Acuitas Therapeutics, Inc. | Pegylated lipids |
| WO2025128696A1 (en) | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025132122A1 (en) | 2023-12-13 | 2025-06-26 | Berlin Institute Of Health | Methods of delivering therapeutics using lipid nanoparticles |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025133105A1 (en) * | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| WO2025140421A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京剂泰医药科技有限公司 | 可电离脂质化合物及其在递送核酸疫苗中的用途 |
| WO2025166323A2 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting lipoprotein (a) expression |
| WO2025174858A1 (en) | 2024-02-15 | 2025-08-21 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| TW202543583A (zh) | 2024-03-01 | 2025-11-16 | 加拿大商阿奎特斯醫療公司 | 用於將治療劑包覆於脂質奈米顆粒中之材料及方法 |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| TW202602839A (zh) | 2024-04-10 | 2026-01-16 | 加拿大商阿奎特斯醫療公司 | 用於脂質奈米顆粒之陽離子脂質化合物 |
| CN118319880B (zh) * | 2024-04-15 | 2025-02-07 | 荣灿生物医药技术(上海)有限公司 | 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用 |
| WO2025230906A1 (en) * | 2024-04-29 | 2025-11-06 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| WO2025231114A1 (en) | 2024-05-01 | 2025-11-06 | Acuitas Therapeutics, Inc. | Method of using lipid nanoparticles for intramuscular delivery |
| WO2025240833A1 (en) | 2024-05-17 | 2025-11-20 | Acuitas Therapeutics, Inc. | Galnac lipid compounds for use in lipid nanoparticles |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026035680A1 (en) | 2024-08-06 | 2026-02-12 | Kernal Biologics, Inc. | Compositions and methods for delivery of agents |
| CN119431176B (zh) * | 2024-11-05 | 2026-02-13 | 汉信生物科技(苏州)有限公司 | 一种可电离阳离子脂质及其制备方法和应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| AU637800B2 (en) | 1989-08-31 | 1993-06-10 | City Of Hope | Chimeric dna-rna catalytic sequences |
| US6365730B1 (en) | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| US6197553B1 (en) | 1994-07-15 | 2001-03-06 | Merck & Co., Inc. | Method for large scale plasmid purification |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| DE69810781T2 (de) | 1997-08-15 | 2003-09-25 | Chisso Corp., Osaka | Polydisperses propylenpolymer und verfahren zu dessen herstellung |
| US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| JP2002502831A (ja) | 1998-02-03 | 2002-01-29 | イネックス ファーマシューティカルズ コーポレイション | 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与 |
| US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
| EP1412065A2 (en) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| WO2004080406A2 (en) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
| NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| WO2007021896A2 (en) | 2005-08-10 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro rna and uses thereof |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| WO2008036841A2 (en) | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| US20100015218A1 (en) | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
| CA2816925C (en) | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| EP2506879A4 (en) | 2009-12-01 | 2014-03-19 | Protiva Biotherapeutics Inc | PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| CA2784568A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Lipid particles for delivery of nucleic acids |
| EP2558074B1 (en) | 2010-04-08 | 2018-06-06 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| EA201390145A1 (ru) | 2010-08-20 | 2013-11-29 | Серулин Фарма Инк. | Конъюгаты, частицы, композиции и связанные с ними способы |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| EP2760477B1 (en) * | 2011-09-27 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
| CA2853685C (en) | 2011-11-04 | 2019-09-03 | Nitto Denko Corporation | Single use system for sterilely producing lipid-nucleic acid particles |
| EP2788006B1 (en) | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| EP3364950A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| BR112019008481A2 (pt) * | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| ES3063077T3 (en) * | 2016-10-26 | 2026-04-15 | Acuitas Therapeutics Inc | Lipid nanoparticle formulations |
| EP3551169A4 (en) * | 2016-12-09 | 2020-09-09 | Sangamo Therapeutics, Inc. | TARGET-SPECIFIC NUCLEASES ADMINISTRATION |
| WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| WO2019089828A1 (en) * | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| CA3080592A1 (en) | 2017-10-31 | 2019-05-09 | Modernatx, Inc. | Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| MY202837A (en) | 2019-01-11 | 2024-05-24 | Acuitas Therapeutics Inc | Lipids for lipid nanoparticle delivery of active agents |
-
2020
- 2020-08-14 US US17/634,516 patent/US20230097090A1/en active Pending
- 2020-08-14 UA UAA202200959A patent/UA129330C2/uk unknown
- 2020-08-14 EP EP24185708.5A patent/EP4454640A3/en active Pending
- 2020-08-14 PE PE2022000237A patent/PE20220968A1/es unknown
- 2020-08-14 MX MX2022001720A patent/MX2022001720A/es unknown
- 2020-08-14 EP EP20765121.7A patent/EP4013385B1/en not_active Revoked
- 2020-08-14 HR HRP20241255TT patent/HRP20241255T1/hr unknown
- 2020-08-14 GB GB2201685.1A patent/GB2600859B/en active Active
- 2020-08-14 BR BR112022002708A patent/BR112022002708A2/pt unknown
- 2020-08-14 FI FIEP20765121.7T patent/FI4013385T3/fi active
- 2020-08-14 ES ES20765121T patent/ES2992930T3/es active Active
- 2020-08-14 SI SI202030493T patent/SI4013385T1/sl unknown
- 2020-08-14 WO PCT/US2020/046407 patent/WO2021030701A1/en not_active Ceased
- 2020-08-14 CA CA3150458A patent/CA3150458A1/en active Pending
- 2020-08-14 GE GEAP202515904A patent/GEAP202515904A/en unknown
- 2020-08-14 KR KR1020227008228A patent/KR20220053599A/ko not_active Ceased
- 2020-08-14 DE DE112020003843.2T patent/DE112020003843T5/de active Pending
- 2020-08-14 LT LTEPPCT/US2020/046407T patent/LT4013385T/lt unknown
- 2020-08-14 PL PL20765121.7T patent/PL4013385T3/pl unknown
- 2020-08-14 JP JP2022508754A patent/JP7753190B2/ja active Active
- 2020-08-14 AU AU2020328596A patent/AU2020328596B2/en active Active
- 2020-08-14 PT PT207651217T patent/PT4013385T/pt unknown
- 2020-08-14 DK DK20765121.7T patent/DK4013385T3/da active
- 2020-08-14 GE GEAP202015904A patent/GEP20257820B/en unknown
- 2020-08-14 ES ES202290010A patent/ES2918001R1/es active Pending
- 2020-08-14 PH PH1/2022/550363A patent/PH12022550363A1/en unknown
- 2020-08-14 HU HUE20765121A patent/HUE068356T2/hu unknown
- 2020-08-14 CR CR20220108A patent/CR20220108A/es unknown
- 2020-08-14 CN CN202080072049.1A patent/CN114901253A/zh active Pending
-
2022
- 2022-02-09 MX MX2025003983A patent/MX2025003983A/es unknown
- 2022-02-09 IL IL290477A patent/IL290477A/en unknown
- 2022-02-11 CL CL2022000351A patent/CL2022000351A1/es unknown
- 2022-02-13 JO JOP/2022/0037A patent/JOP20220037A1/ar unknown
- 2022-02-14 DO DO2022000038A patent/DOP2022000038A/es unknown
- 2022-03-07 CO CONC2022/0002685A patent/CO2022002685A2/es unknown
- 2022-03-11 EC ECSENADI202218209A patent/ECSP22018209A/es unknown
-
2025
- 2025-07-31 JP JP2025128566A patent/JP2025173509A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241255T1 (hr) | Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina | |
| JP7678758B2 (ja) | 脂質封入ｒｎａナノ粒子の製造方法 | |
| CA2532228C (en) | Lipid encapsulated interfering rna | |
| JPWO2021030701A5 (https=) | ||
| US9687448B2 (en) | Nucleic acid lipid particle formulations | |
| US10081598B2 (en) | Cationic lipid | |
| JP2011507534A5 (https=) | ||
| JP2019508371A5 (https=) | ||
| IL316479A (en) | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery | |
| US9873669B2 (en) | Cationic lipid | |
| JP2018521052A5 (https=) | ||
| CN103857654A (zh) | 用于定向药物输送和增强siRNA活性的化合物 | |
| WO2024046448A1 (en) | Lyophilized formulations and liquid formulations of lipid nanoparticles | |
| KR101685304B1 (ko) | 간 조직 특이적 유전자 발현 억제인자 전달용 나노리포좀 | |
| US10500158B2 (en) | Cationic lipid | |
| KR20250111222A (ko) | 신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
| JPWO2023144798A5 (https=) | ||
| TH2201000939A (th) | อนุภาคนาโนไขมันที่ถูกปรับปรุงสำหรับการนำส่งกรดนิวคลีอิก | |
| WO2025160127A1 (en) | Ionizable lipids and compositions thereof for delivery of therapeutic agents | |
| CA3287902A1 (en) | Method for producing nucleic acid-encapsulated lipid nanoparticles | |
| JP2026009862A5 (https=) | ||
| WO2026044248A1 (en) | Ionizable cationic lipids and lipid nanoparticle compositions | |
| NZ820531B2 (en) | Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof |